Table 1.
The baseline characteristics of identified studies and enrolled patients.
| Study | Country | Sample size | Age (years) | Male (%) | Size of lesion | Total area of CNV | Angiographic subtype of lesion | Intervention | Follow-up (years) | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|
| Gragoudas, 2004 [29] | US, Canada, Europe, Israel, Australia, and South America | 1,208 | 75.5 | 40.9 | 4.0 | NA | Predominantly classic: 306; minimally classic: 426; occult with no classic: 458 | Pegaptanib; sham injection | 1.0 | 5 |
| Brown, 2006 [30] | US, France, Germany, Hungary, Czech Republic, and Australia | 423 | 77.0 | 50.1 | 1.9 | 1.4 | Predominantly classic: 410; minimally classic: 12; occult with no classic: 1 | Ranibizumab; verteporfin | 2.0 | 5 |
| Rosenfeld, 2006 [31] | US | 716 | 77.0 | 35.2 | 4.4 | 4.2 | Predominantly classic: 1; minimally classic: 264; occult with no classic: 451 | Ranibizumab; sham injection | 2.0 | 5 |
| Regillo, 2008 [32] | US | 184 | 78.4 | 40.2 | 4.2 | 3.6 | Predominantly classic: 35; minimally classic: 69; occult with no classic: 79 | Ranibizumab; sham injection | 2.0 | 4 |
| Sacu, 2009 [33] | Austria | 28 | 78.0 | 32.1 | NA | NA | NA | Bevacizumab; triamcinolone | 1.0 | 4 |
| Tufail, 2010 [34] | UK | 131 | 80.0 | 59.5 | 6.1 | 3.5 | Predominantly classic: 49; minimally classic: 151 | Bevacizumab; verteporfin | 1.0 | 5 |
| Subranmanian, 2010 [35] | US | 22 | 78.6 | 95.5 | NA | NA | Predominantly classic: 3; minimally classic: 4; occult with no classic: 15 | Bevacizumab; ranibizumab | 1.0 | 3 |
| Biswas, 2011 [36] | India | 104 | 63.9 | 48.1 | NA | NA | NA | Bevacizumab; ranibizumab | 1.5 | 3 |
| CATT, 2011 [37] | US | 1,185 | 79.3 | 38.2 | NA | NA | NA | Bevacizumab; ranibizumab | 2.0 | 4 |
| Kodjikian, 2013 [38] | France | 374 | 79.7 | 33.7 | NA | 1.9 | NA | Bevacizumab; ranibizumab | 1.0 | 4 |
| Chakravarthy, 2013 [39] | UK | 525 | 77.7 | 40.0 | 3.6 | NA | NA | Bevacizumab; ranibizumab | 2.0 | 5 |
| Krebs, 2013 [40] | Austria | 317 | 77.2 | 36.3 | NA | NA | NA | Bevacizumab; ranibizumab | 1.0 | 5 |
| Scholler, 2014 [41] | Austria | 55 | 80.1 | 29.1 | 1.9 | NA | NA | Bevacizumab; ranibizumab | 1.0 | 3 |
| Schmidt-Erfurth, 2014 [42] | US, Canada, Europe, the Middle East, the Asia-Pacific region, and Latin America | 2,412 | 75.9 | 42.9 | 7.6 | 7.2 | Predominantly classic: 631; minimally classic: 838; occult with no classic: 926 | Aflibercept; ranibizumab | 2.0 | 4 |
| Berg, 2015 [43] | Norway | 431 | 78.3 | 32.5 | 7.0 | NA | NA | Bevacizumab; ranibizumab | 2.0 | 5 |
| Schauwvlieghe, 2016 [44] | Netherlands | 327 | 78.0 | 44.0 | 2.7 | NA | Predominantly classic: 85; minimally classic: 51; occult with no classic: 177 | Bevacizumab; ranibizumab | 1.0 | 4 |
| Liu, 2019 [45] | China | 124 | 66.1 | 67.7 | NA | NA | Predominantly classic: 61; minimally classic: 29; occult with no classic: 31 | Conbercept; sham injection | 1.0 | 4 |
| Gillies, 2019 [46] | Australia | 281 | 77.6 | 47.3 | NA | NA | NA | Aflibercept; ranibizumab | 1.0 | 4 |
∗CNV: choroidal neovascularization; NA: not available.